Health innovation networks - formerly Academic Health Science Networks, or AHSNs - have a key role in connecting industry innovators and healthcare partners, with the aims of transforming patient outcomes and generating economic growth within the health system. While our overarching funding comes from NHS England and the Government’s Office for Life Sciences, for some programmes of work - where appropriate - we develop joint working agreements with commercial organisations.
HINs don’t directly endorse specific companies, innovations or approaches, but present promising innovative solutions for colleagues in the health and care system to learn from and potentially explore in further detail.
A Transfer of Value is usually a direct payment from industry to the HIN towards a HIN project or programme, or a secondment of staff from industry to support HIN projects. In some instances this includes additional funding which enables the HINs and NHS to reach more patients, while ensuring the health and care system benefit from the very best innovations in health and care.
It does not include HIN provision of services to a commercial partner – for example, where the HIN is undertaking a commission to provide evaluation support.
We publish summaries of all transfers of value from industry to Health Innovation Wessex. These include donations from industry to Health Innovation Wessex (formerly Wessex AHSN), or Joint Working Agreements between industry and Health Innovation Wessex which may comprise funding or other support. On this page, you can find our declarations of current partnerships within the Resources section on the right. For information relating to joint working before 2022, contact us at enquiries@hiwessex.net and we will respond to your request.
Please check back regularly to see any additions published as a result of our active programme of updates.
| Organisations involved | Start date | End date | Monetary value (£) | Reason for benefit |
| Sanofi and Wessex AHSN | January 2023 | December 2023 | Total costs (indirect): 9,848.71 | To improve patient access to lipid services, delivering a plan to review pathways and provision in Wessex. |
| Boehringer Ingelheim and Wessex AHSN | 15 June 2023 | 15 June 2023 | Nil | NHS Confed Expo expert panel speaker agreement. |
| Amgen and Wessex AHSN t/a Health Innovation Wessex | September 2023 | February 2024 | Total costs (indirect): 3,360.00 | To improve services for patients in Dorset with suspected familial hypercholesterolaemia, by reviewing the current pathway for genetic testing and co-producing an action plan for change. |
Featured video